Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND & AIMS">Genetic factors associated with non-alcoholic fatty liver disease (NAFLD) remain incompletely understood. To date, most genome-wide association studies (GWASs) have adopted radiologically assessed hepatic triglyceride content as the reference phenotype and so cannot address steatohepatitis or fibrosis. We describe a GWAS encompassing the full spectrum of histologically characterised NAFLD.</AbstractText>METHODS: <AbstractText Label="METHODS">The GWAS involved 1,483 European NAFLD cases and 17,781 genetically matched controls. A replication cohort of 559 NAFLD cases and 945 controls was genotyped to confirm signals showing genome-wide or close to genome-wide significance.</AbstractText>RESULTS: <AbstractText Label="RESULTS">Case-control analysis identified signals showing p values ≤5 × 10-8 at 4 locations (chromosome [chr] 2 GCKR/C2ORF16; chr4 HSD17B13; chr19 TM6SF2; chr22 PNPLA3) together with 2 other signals with p <1 × 10-7 (chr1 near LEPR and chr8 near IDO2/TC1). Case-only analysis of quantitative traits showed that the PNPLA3 signal (rs738409) had genome-wide significance for steatosis, fibrosis and NAFLD activity score and a new signal (PYGO1 rs62021874) had close to genome-wide significance for steatosis (p = 8.2 × 10-8). Subgroup case-control analysis for NASH confirmed the PNPLA3 signal. The chr1 LEPR single nucleotide polymorphism also showed genome-wide significance for this phenotype. Considering the subgroup with advanced fibrosis (≥F3), the signals on chr2, chr19 and chr22 maintained their genome-wide significance. Except for GCKR/C2ORF16, the genome-wide significance signals were replicated.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">This study confirms PNPLA3 as a risk factor for the full histological spectrum of NAFLD at genome-wide significance levels, with important contributions from TM6SF2 and HSD17B13. PYGO1 is a novel steatosis modifier, suggesting that Wnt signalling pathways may be relevant in NAFLD pathogenesis.</AbstractText>LAY SUMMARY: <AbstractText Label="LAY SUMMARY">Non-alcoholic fatty liver disease is a common disease where excessive fat accumulates in the liver and may result in cirrhosis. To understand who is at risk of developing this disease and suffering liver damage, we undertook a genetic study to compare the genetic profiles of people suffering from fatty liver disease with genetic profiles seen in the general population. We found that particular sequences in 4 different areas of the human genome were seen at different frequencies in the fatty liver disease cases. These sequences may help predict an individual's risk of developing advanced disease. Some genes where these sequences are located may also be good targets for future drug treatments.</AbstractText>

A regulatory element associated to NAFLD in the promoter of DIO1 controls LDL-C, HDL-C and triglycerides in hepatic cells

Integrative regulation of hLMR1 by dietary and genetic factors in nonalcoholic fatty liver disease and hyperlipidemia

Integrative analysis of liver-specific non-coding regulatory SNPs associated with the risk of coronary artery disease

Genetic Variation in PNPLA3 Confers Susceptibility to Nonalcoholic Fatty Liver Disease

A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids

Genetic Association of Lipids and Lipid-Lowering Drug Target Genes with Non-Alcoholic Fatty Liver Disease

Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits

Genetic Variations and Nonalcoholic Fatty Liver Disease: Field Synopsis, Systematic Meta-Analysis, and Epidemiological Evidence

Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

Trans -Ancestry Fine Mapping and Molecular Assays Identify Regulatory Variants at the ANGPTL8 HDL-C GWAS Locus

Population‐based meta‐analysis and gene‐set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids

Gwas-Identified Common Variants with Nonalcoholic Fatty Liver Disease in Chinese Children

The relationship between genetic liver fat and coronary heart disease is explained by apoB-containing lipoproteins

Shared genetic etiology and causal relationships among NAFLD, obesity and glycemic traits: A large-scale genome-wide cross-trait analysis.

A Network-Based Approach Reveals the Dysregulated Transcriptional Regulation in Non-Alcohol Fatty Liver Disease

Genetic Variation in TBC1 Domain Family Member 1 Gene Associates with the Risk of Lean NAFLD Via High-Density Lipoprotein

Abstract 13791: Non-Alcoholic Fatty Liver Disease Risk SNP Variants Affect Lipid Metabolism

Genetics Is of the Essence to Face NAFLD

rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

Functional Investigation and Two-Sample Mendelian Randomization Study of Non-Alcoholic Fatty Liver Disease Hub Genes Obtained by WGCNA

Potential causal links between genetic variants in SAMM50, SUGP1, MAU2, and GATAD2A and liver fat in individuals with normal weight